Biomarin agreed to acquire Alesta Therapeutics’ lead oral small-molecule candidate ALE-1 for $275 million upfront, valuing the deal at up to $490 million with milestones. The asset is in phase I/IIa for hypophosphatasia, adding another skeletal-disease program to Biomarin’s portfolio focused on mineralization biology. Analysts framed the transaction as consistent with Biomarin’s broader interest in inorganic pyrophosphate (PPi)–related pathways after a prior molecule tied to the same axis was discontinued. The Alesta acquisition is expected to bring the company closer to building a larger addressable rare disease market beyond its existing footprint in ultra-rare skeletal disorders. The deal underscores how investor and corporate attention remains concentrated on mechanisms that can shift bone mineralization, even when earlier programs fail—particularly when there is a clear differentiation on route of administration or patient selection strategy.